These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16302098)

  • 1. Attenuation and immunogenicity of recombinant yellow fever 17D-dengue type 2 virus for rhesus monkeys.
    Galler R; Marchevsky RS; Caride E; Almeida LF; Yamamura AM; Jabor AV; Motta MC; Bonaldo MC; Coutinho ES; Freire MS
    Braz J Med Biol Res; 2005 Dec; 38(12):1835-46. PubMed ID: 16302098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates.
    Guirakhoo F; Pugachev K; Arroyo J; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Draper K; Monath TP
    Virology; 2002 Jun; 298(1):146-59. PubMed ID: 12093182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.
    Guirakhoo F; Arroyo J; Pugachev KV; Miller C; Zhang ZX; Weltzin R; Georgakopoulos K; Catalan J; Ocran S; Soike K; Ratterree M; Monath TP
    J Virol; 2001 Aug; 75(16):7290-304. PubMed ID: 11462001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction, characterization and immunogenicity of recombinant yellow fever 17D-dengue type 2 viruses.
    Caufour PS; Motta MC; Yamamura AM; Vazquez S; Ferreira II; Jabor AV; Bonaldo MC; Freire MS; Galler R
    Virus Res; 2001 Nov; 79(1-2):1-14. PubMed ID: 11551641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys.
    Trindade GF; Marchevsky RS; Fillipis AM; Nogueira RM; Bonaldo MC; Acero PC; Caride E; Freire MS; Galler R
    An Acad Bras Cienc; 2008 Jun; 80(2):311-21. PubMed ID: 18506257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
    Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
    Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single amino acid substitution in the envelope protein of chimeric yellow fever-dengue 1 vaccine virus reduces neurovirulence for suckling mice and viremia/viscerotropism for monkeys.
    Guirakhoo F; Zhang Z; Myers G; Johnson BW; Pugachev K; Nichols R; Brown N; Levenbook I; Draper K; Cyrek S; Lang J; Fournier C; Barrere B; Delagrave S; Monath TP
    J Virol; 2004 Sep; 78(18):9998-10008. PubMed ID: 15331733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and biological properties of yellow fever 17D/dengue type 1 recombinant virus.
    Mateu GP; Marchevsky RS; Liprandi F; Bonaldo MC; Coutinho ES; Dieudonné M; Caride E; Jabor AV; Freire MS; Galler R
    Trans R Soc Trop Med Hyg; 2007 Mar; 101(3):289-98. PubMed ID: 17169387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.
    Guirakhoo F; Pugachev K; Zhang Z; Myers G; Levenbook I; Draper K; Lang J; Ocran S; Mitchell F; Parsons M; Brown N; Brandler S; Fournier C; Barrere B; Rizvi F; Travassos A; Nichols R; Trent D; Monath T
    J Virol; 2004 May; 78(9):4761-75. PubMed ID: 15078958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.
    Guirakhoo F; Kitchener S; Morrison D; Forrat R; McCarthy K; Nichols R; Yoksan S; Duan X; Ermak TH; Kanesa-Thasan N; Bedford P; Lang J; Quentin-Millet MJ; Monath TP
    Hum Vaccin; 2006; 2(2):60-7. PubMed ID: 17012873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model.
    Chambers TJ; Liang Y; Droll DA; Schlesinger JJ; Davidson AD; Wright PJ; Jiang X
    J Virol; 2003 Mar; 77(6):3655-68. PubMed ID: 12610141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses.
    Mantel N; Girerd Y; Geny C; Bernard I; Pontvianne J; Lang J; Barban V
    Vaccine; 2011 Sep; 29(38):6629-35. PubMed ID: 21745519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.
    Barban V; Munoz-Jordan JL; Santiago GA; Mantel N; Girerd Y; Gulia S; Claude JB; Lang J
    Virology; 2012 Aug; 429(2):91-8. PubMed ID: 22542002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Production of yellow fever 17DD vaccine virus in primary culture of chicken embryo fibroblasts: yields, thermo and genetic stability, attenuation and immunogenicity.
    Freire MS; Mann GF; Marchevsky RS; Yamamura AM; Almeida LF; Jabor AV; Malachias JM; Coutinho ES; Galler R
    Vaccine; 2005 Mar; 23(19):2501-12. PubMed ID: 15752837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurovirulence of yellow fever 17DD vaccine virus to rhesus monkeys.
    Marchevsky RS; Freire MS; Coutinho ES; Galler R
    Virology; 2003 Nov; 316(1):55-63. PubMed ID: 14599790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos.
    Marchevsky RS; da Luz Leal M; Homma A; Coutinho ES; Camacho LA; Jabor AV; Galler R; Freire MS
    Biologicals; 2006 Sep; 34(3):191-7. PubMed ID: 16326110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.